The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.
about
Treatment with echinocandins during continuous renal replacement therapyAssembly of the yeast cell wall. Crh1p and Crh2p act as transglycosylases in vivo and in vitro.Comparison of echinocandin antifungalsEpidemiology of invasive candidiasis: a persistent public health problemCandida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance programPharmacokinetics of caspofungin acetate to guide optimal dosing in cats.Cell wall integrity signaling in Saccharomyces cerevisiaeFKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.Macrocyclic drugs and synthetic methodologies toward macrocyclesMicafungin in the treatment of invasive candidiasis and invasive aspergillosisRegulation of cell wall biogenesis in Saccharomyces cerevisiae: the cell wall integrity signaling pathway.Genetically recombinant antibodies: new therapeutics against candidiasis.Serum differentially alters the antifungal properties of echinocandin drugs.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literatureA RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets.Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidiaIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Echinocandin antifungals: review and update.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.Resistance to echinocandin-class antifungal drugs.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis.Candida endophthalmitis: focus on current and future antifungal treatment options.Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of CandidemiaEvaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.Paradoxical echinocandin activity: a limited in vitro phenomenon?Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibilityAntifungal drug resistance: do molecular methods provide a way forward?New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Antifungals to treat Candida albicans.Anidulafungin: an evidence-based review of its use in invasive fungal infections.Novel small molecules for the treatment of infections caused by Candida albicans: a patent review (2002-2010).Fungal endophthalmitis.The Eagle-like effect of echinocandins: what's in a name?Identification and management of invasive mycoses in internal medicine: a road-map for physicians.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Synthetic Strategy and Anti-Tumor Activities of Macrocyclic Scaffolds Based on 4-Hydroxyproline.Management of candidemia in patients with Clostridium difficile infection.Echinocandin Resistance in Candida Species: a Review of Recent Developments.In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.
P2860
Q27012864-E43198B0-7C8A-41B3-89EF-612DB2C56315Q27937435-BDC75C24-66D5-4715-96DC-7950E48F798AQ28273738-0D31B830-44B1-423E-BB09-2131BB295D43Q29616758-48A24F9D-6F21-4984-A148-B621277BEFDAQ30445376-43BE51F7-C884-4BCB-BA67-D4B1FAC947DBQ33757912-C5495F30-7AA6-4F8C-AC8D-25CA5210BDFFQ33939988-118FB69A-A39F-4AC5-ADEC-91272161FF4BQ34737334-8B5B0397-D187-476F-9768-F8BA6408A018Q34740721-84D5834D-8390-4A89-A514-C65ECEA80246Q35026516-60C850C3-0E27-48EC-8836-C0829EFA3649Q35620450-C8D1E6AA-9B26-43C8-926B-DF38EC744EB7Q35681522-6D633533-D3B5-4D61-A51B-5890739E0B5FQ35840860-E7E5D68F-13F9-442C-A010-57BC6B0B9DEEQ35959484-2FEF7BC0-9826-4704-9585-E6A5B0A77C78Q36250421-2E196CF7-3190-4C4F-B85D-BC42CD79BD3FQ36422666-F8C598AF-36D3-453E-BF48-A5BE8433A3D0Q36425025-A9CCFF6E-301B-4B3C-8962-8432C4616F79Q36441524-4CC2B62D-5688-42A8-AACA-6C2318124987Q36828156-B3CBFC3D-941F-460D-8202-D02392F9264BQ36849595-A19A107B-DFC8-4F72-86FA-0025F49BFF9AQ36932989-D29A43E6-E62E-448B-8FB0-51AA2D767F20Q36949545-D789113B-D44B-4251-8AA1-1EF4861A35CEQ37015976-BAC3B6D9-B97A-4667-8E9C-C8BF27CBECC9Q37229198-6ADD15C2-67C6-450A-A58C-E753ACAC6B3BQ37291442-A762C977-CA8E-42B1-9B91-3F4C494CE2CCQ37405284-A2E5A0BE-9752-4D6C-B380-16A8B2FFF1D3Q37544444-F41465C9-0796-4A1B-BF52-1CE87A9155D1Q37554059-006ACCB5-29F3-40EF-B52A-4A9A8636A37FQ37608276-87229D46-96AB-46B7-9100-40A0434B2CBEQ37763928-67A0905E-8098-4247-A1DE-78225ED350DEQ37827345-8E26645F-00EF-489C-91D9-14FD2F05875BQ37829442-41391DF4-4F6B-46DC-8E6F-F4CCB59ABD4DQ37960568-0F7AC72B-4002-42B2-8738-DB2B3185A835Q38153458-248823F9-5A15-42BB-BFCF-266EF499AA36Q38215670-6E457CD5-2497-4866-A3E1-CDE1EC72FF0FQ38681635-A21455A3-DA23-4B41-88F8-23A92217858FQ38793011-6731A051-1F4B-4D20-90A5-15A43EF51504Q38851595-AAC7420B-D872-4109-ADA7-FFE794E2AA1AQ38988521-9071E126-F67F-4F11-BA73-D77251BE8F50Q39077602-43508DD1-B0BB-4D1F-A6B9-BC07C5CC9C92
P2860
The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The echinocandin antifungals: ...... pectrum and clinical efficacy.
@ast
The echinocandin antifungals: ...... pectrum and clinical efficacy.
@en
type
label
The echinocandin antifungals: ...... pectrum and clinical efficacy.
@ast
The echinocandin antifungals: ...... pectrum and clinical efficacy.
@en
prefLabel
The echinocandin antifungals: ...... pectrum and clinical efficacy.
@ast
The echinocandin antifungals: ...... pectrum and clinical efficacy.
@en
P2860
P1476
The echinocandin antifungals: ...... pectrum and clinical efficacy.
@en
P2093
Nathan P Wiederhold
Russell E Lewis
P2860
P304
P356
10.1517/13543784.12.8.1313
P407
P577
2003-08-01T00:00:00Z